186RNL not checked

Cerenome · Rhenium-186 Nanoliposome

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
4 active
5 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well…”In the company’s words, NCT01906385 on ClinicalTrials.gov
Tested for
Glioma (2 trials), Leptomeningeal Metastasis, Ependymoma, High Grade Gliomas
Main trialPhase 1/2
“This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment. The study uses a modified Fibonacci dose escalation, followed by an expansion at the maximum tolerated dose (MTD) to determine efficacy. The starting absorbed dose is 1mCi in a volume of 0.660mL.”In the company’s words, NCT01906385 on ClinicalTrials.gov
Other names
Retreatment Rhenium Liposome · Rhenium-186 Nanoliposome · Rhenium Liposome Treatment

Other drugs for Glioma

All 126 drugs for Glioma

Coming up4

Changes1

Last 90 days

Trials5

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting Apr 2027 Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Phase 1/2Recruiting 31 Jul 2027 Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
Phase 1Recruiting 1 Mar 2028 Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
Phase 1Recruiting Mar 2028 Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
Phase 1Completed 19 Oct 2026 Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow 186RNL

Following is part of Solo: you see every change to 186RNL the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in